A5072732293- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- PARP inhibition in cancer therapy
- Ubiquitin and proteasome pathways
- RNA Research and Splicing
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Metabolism, Diabetes, and Cancer
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Advances in Oncology and Radiotherapy
- Science, Research, and Medicine
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
Agency for Science, Technology and Research
2020-2024
Genome Institute of Singapore
2020-2024
Nanyang Technological University
2021
The identification of cancer driver genes from sequencing data has been crucial in deepening our understanding tumor biology and expanding targeted therapy options. However, apart the most commonly altered genes, mechanisms underlying contribution other mutations to acquisition remain understudied. Leveraging on whole-exome largest Asian lung adenocarcinoma (LUAD) cohort (n = 302), we now functionally assess mechanistic role a novel driver, PARP4.
Abstract Mis-sense mutations affecting TP53 promote carcinogenesis both by inactivating tumor suppression, and conferring pro-carcinogenic activities. We report here that p53 DNA-binding domain (DBD) transactivation (TAD) mis-sense mutants unexpectedly activate epidermal growth factor receptor (EGFR) signaling via distinct, previously unrecognized molecular mechanisms. DBD- TAD-specific exhibited different cellular localization induced distinct gene expression profiles. In multiple tissues,...
Abstract The 15th annual Frontiers in Cancer Science (FCS) conference gathered scientific experts who shared the latest research converging upon several themes of cancer biology. These included dysregulation metabolism, cell death, and other signaling processes cells; using patient “omics” datasets single-cell spatial approaches to investigate heterogeneity, understand therapy resistance, identify targets; innovative strategies for inhibiting tumors, including rational drug combinations...
Abstract Lung cancer is the leading cause of mortality globally, with lung adenocarcinoma being most prevalent subtype. The discovery driver mutations has paved way for use targeted therapy, notably EGFR inhibitors, in management advanced disease. However, effectiveness therapy limited firstly by eventual development treatment resistance, and secondly sizeable percentage cases which remain unknown. Furthermore, (LUAD) Asians known to exhibit a molecular profile distinct from that Caucasians,...